Sakar Healthcare (NSE:SAKAR) Research & Development: ₹0 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:SAKAR Sakar Healthcare Ltd NSE:SAKAR
60 GF Score
Price ₹904.45
GF Value ₹540.00
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Sakar Healthcare Research & Development?

Sakar Healthcare NSE:SAKAR +4.74% 60 Research & Development is ₹0 Mil as of Mar. 2026. GuruFocus rates NSE:SAKAR with a GF Score™ of 60/100 and a GF Value™ of ₹540.00 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Sakar Healthcare's Research & Development for the three months ended in Mar. 2026 was ₹0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0 Mil.

Sakar Healthcare  (NSE:SAKAR) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Sakar Healthcare Research & Development Related Terms

Sakar Healthcare Research & Development Historical Data

* Premium members only.

The historical data trend for Sakar Healthcare's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sakar Healthcare Research & Development Chart

Sakar Healthcare Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.14 7.45 6.18 6.40 0.00

Sakar Healthcare Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:SAKAR
60GF Score
Sakar Healthcare Ltd NSE:SAKAR
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sakar Healthcare Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ₹0 Mil mean?
Sakar Healthcare (NSE:SAKAR) has a Research & Development of ₹0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Sakar Healthcare and its competitors.
Is Sakar Healthcare's Research & Development too high?
Sakar Healthcare's current Research & Development is ₹0 Mil. Overall, Sakar Healthcare has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sakar Healthcare's Research & Development compare to ZTS and UTHR?
Sakar Healthcare's Research & Development of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Sakar Healthcare and its competitors. Sakar Healthcare's current Research & Development is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sakar Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Sakar Healthcare (NSE:SAKAR) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹540.00, compared to a current price of ₹904.45 — trading 67.5% above its estimated fair value. The current Research & Development is ₹0 Mil. Sakar Healthcare's overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Sakar Healthcare (NSE:SAKAR), the current Research & Development is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sakar Healthcare (NSE:SAKAR) Overvalued in 2026?

Based on GuruFocus' analysis, Sakar Healthcare stock appears to be overvalued. The current stock price of ₹904.45 is trading 67.5% above its estimated GF Value™ of ₹540.00. GuruFocus considers Sakar Healthcare to be Significantly Overvalued.

Key valuation signals for NSE:SAKAR:

  • Research & Development: ₹0 Mil
  • GF Value™: ₹540.00 vs. price of ₹904.45 (67.5% above fair value)
  • GF Score™: 60/100 with 6 warning signs

No single metric tells the full story. See the NSE:SAKAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sakar Healthcare Business Description

Address 406, Silver Oaks Comm. Complex, Opposite Arun Society, Paldi, Ahmedabad, GJ, IND, 382 007
Sakar Healthcare Ltd is engaged in manufacturing Pharmaceutical products providing Liquid Orals, Cephalosporin Tablet, Capsule, Dry Powder Syrup, Dry Powder Injections, Liquid Injectables (SVP) in Ampoules and Vials & Lyophilized Injections. The company offers its products to Sri Lanka, the Philippines, Vietnam, Cambodia, Sudan, Myanmar, Mauritius, Costa Rica, Panama, El Salvador and Paraguay.
60GF Score

Get the complete analysis for NSE:SAKAR

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹904.45
Price
₹540.00
GF Value